Galectin-3: Cross-Organ Fibrosis Biomarker & Drug Target
Galectin-3: β-galactoside-binding lectin from activated macrophages; FDA-cleared heart failure biomarker. Cross-organ fibrosis role and GB0139 for IPF.
1. Why Galectin-3 Matters
Galectin-3 (Gal-3, gene LGALS3) is the only chimera-type member of the β-galactoside-binding lectin family. Secreted by activated M2 macrophages and myofibroblasts, it drives ECM remodeling, inflammation, and fibrosis.
Three features anchor its clinical value:
- FDA clearance (2010) of the BGM Galectin-3 Test as a heart failure prognostic biomarker
- Cross-organ relevance: elevated in cardiac, hepatic, pulmonary, and renal fibrosis
- Drug target validation: the inhibitor GB0139 (inhaled Gal-3 inhibitor) has advanced toward Phase 3 in IPF (Galecto)
This article reviews Gal-3 biology, organ-level clinical significance, and its evolution as an anti-fibrotic drug target.
2. Structure and Function
A Unique Chimera-Type Lectin
The galectin family (15 members) is classified by carbohydrate recognition domain (CRD) architecture:
- Proto-type (Gal-1, -2, -5, -7, -10, -11, -13, -14, -15): single CRD
- Tandem-repeat type (Gal-4, -6, -8, -9, -12): two linked CRDs
- Chimera type: Gal-3 alone — N-terminal collagen-like domain + CRD
The N-terminal domain enables Gal-3 oligomerization into lattice-like networks that cross-link cell-surface glycoproteins, generating potent signaling.
Core Biological Actions
- TGF-β amplification: stabilizes β-catenin and blocks TGF-βR endocytosis, sustaining TGF-β/Smad signaling
- Macrophage M2 polarization: drives M2 differentiation under IL-4, serves as a hallmark of scar-associated / lipid-associated macrophages
- Myofibroblast activation: directly promotes fibroblast-to-myofibroblast conversion
- NLRP3 inflammasome activation: sustains chronic inflammation
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
3. Organ-Level Clinical Significance
Heart: Prognostic Marker in Heart Failure
- PRIDE study (2006): elevated Gal-3 strongly predicted 60-day mortality in acute HF
- HF-ACTION: in chronic HFrEF, Gal-3 ≥17.8 ng/mL was an independent predictor of cardiovascular events
- FDA-cleared cutoffs: 17.8 ng/mL (intermediate risk), 25.9 ng/mL (high risk)
- Guidelines: 2017 AHA/ACC update assigned Gal-3 a Class IIb recommendation for HF risk stratification
Liver: MASH and Cirrhosis
- Useful for distinguishing F2-F3 in MASH (AUROC ~0.75), but MASH specificity lags FibroScan and ELF
- Robustly elevated in cirrhosis and HCC; independent prognostic marker regardless of fibrosis stage
Lung: IPF and Progressive Fibrosis
- IPF patients show elevated BAL and serum Gal-3, with predictive value for acute exacerbations (Ho et al., Thorax 2016)
- GB0139 Phase 2b (Galecto) reported reduced serum Gal-3 and slowed FVC decline
- Post-COVID pulmonary fibrosis also identifies Gal-3 as a candidate progression marker
Kidney: CKD and Cardiorenal Syndrome
- Strongly inversely correlated with eGFR — though partly reflecting reduced renal clearance
- Especially valuable in combined CKD + HF (cardiorenal syndrome) for prognostication
4. Use in Preclinical Research
Measuring Gal-3 in Animal Models
- Serum Gal-3 ELISA kits (R&D Systems DuoSet and others) are available for mouse and rat
- Correlates with fibrosis progression in CCl4, bleomycin pulmonary fibrosis, and UUO models
- IHC confirms colocalization with macrophage markers
The Lgals3^-/- Knockout Phenotype
- Markedly attenuated pulmonary fibrosis in bleomycin models (Mackinnon et al., AJRCCM 2012)
- Similar protection in CCl4 liver fibrosis
- Gal-3 loss consistently reduces fibrosis — strong genetic evidence for its role
5. Status as a Drug Target
Inhibitor Pipeline
| Compound | Developer | Route | Indication | Stage |
|---|---|---|---|---|
| GB0139 (TD139) | Galecto | Inhaled (DPI) | IPF | Phase 2b complete, Phase 3 planned |
| GB1211 | Galecto / Bristol Myers Squibb | Oral small molecule | NASH/cirrhosis | Phase 2a |
| Belapectin (GR-MD-02) | Galectin Therapeutics | IV | NASH cirrhosis + portal hypertension | Phase 2b/3 NAVIGATE |
| LJPC-1010 | La Jolla Pharmaceutical | — | Discontinued | — |
GB0139 (IPF) Highlights
- Inhaled small-molecule inhibitor — selectively targets airway macrophages
- GALACTIC-1 Phase 2b (2021): slowed FVC decline over 12 weeks with good tolerability
- Phase 3 GALACTIC-HPS has been announced
- Combination potential with pirfenidone and nintedanib is widely anticipated
Belapectin (NASH Cirrhosis) — NAVIGATE Trial
- Endpoint: prevention of varices formation in compensated cirrhosis with portal hypertension
- Phase 2b showed significant benefit in a specific subgroup (no baseline varices)
- A positive Phase 3 could establish a new category of "downstream-complication" anti-fibrotic drugs
6. FAQ
Q1: Gal-3 or ELF — which should we prioritize?
It depends on the use case. ELF has higher liver-fibrosis specificity, while Gal-3 is cross-organ and reflects macrophage activation. For MASH patients with concurrent cardiac or renal disease, Gal-3 adds real complementary value.
Q2: How widely is Gal-3 used in heart failure practice?
Routinely in US cardiology clinics; limited domestically in Japan due to lack of reimbursement. Positioned as a complement to NT-proBNP — standard practice uses the two together rather than Gal-3 alone.
Q3: Where can I source Lgals3 KO mice?
JAX Stock #006338 (B6.Cg-Lgals3^tm1Poi/J) is the most widely used, on a C57BL/6J background. Reduced fibrosis phenotype is robustly reproducible across BLM, UUO, and CCl4 models.
Q4: Will GB0139 replace pirfenidone or nintedanib?
No — combination is the leading development strategy. Galectin inhibition hits a distinct pathway (macrophage activation) from current anti-fibrotics, creating additive or synergistic potential. IPF's large unmet need accelerates combination development.
Q5: How should we evaluate Gal-3 inhibition in preclinical models?
- Genetic: Lgals3 KO mice or AAV-shRNA
- Pharmacologic: GB0139 (available as research reagent for in-vivo use) or GB1211
- Functional endpoints: the standard triad is serum Gal-3 + hydroxyproline + macrophage FACS (F4/80+CD206+)
Related Articles
- ECM Turnover Markers (Pro-C3 and others) — Sister biomarker family
- ELF Score Complete Guide — Liver-specific non-invasive marker
- Fibrosis Biomarkers Comprehensive Guide — Cross-organ biomarker landscape
- TGF-β/Smad Pathway — The key pathway Gal-3 amplifies
- IPF Treatment Landscape 2025 — Where GB0139 fits
- Cardiac Fibrosis and HFpEF — Gal-3's role in heart failure
- Mechanisms of Inflammation — Macrophage activation foundations
References
- de Boer RA, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11(9):811-817. PMID: 19648160
- van Kimmenade RR, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48(6):1217-1224. PMID: 16979009
- Mackinnon AC, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185(5):537-546. PMID: 22095546
- Hirani N, et al. Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2021;57(5):2002559. PMID: 33008938
- Chalasani N, et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020;158(5):1334-1345. PMID: 31812510
- Henderson NC, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA. 2006;103(13):5060-5065. PMID: 16549783
- Yancy CW, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2017;70(6):776-803. PMID: 28461007